Lumida
/ARDX
⌘K
Ardelyx Inc

Ardelyx Inc

ARDX
$5.20USD↑+1.46%+0.08 today

MARKET CAP

1.3B

P/E (TTM)

—

FWD P/E

41.4x

DAY RANGE

$5 – $5

52W RANGE

$4
$8

AI Summary

Stalk
Sell NowMedium

ARDX is entrenched in a Stage 4 decline with a bearish medium-term bias confirmed by active lower-highs and lower-lows under declining EMAs. Price is pulling back into the dynamic 9/21/50 EMA resistance zone from oversold conditions, providing a clear sell execution area. Under our Speculative strategy’s high-selectivity framework, we will execute immediate sells at this resistance on visible rejection rather than waiting for further downside.

  • ↑Total revenue grew 38% YoY to $93.4M; Ibsrella sales up 58%.
  • ↑Cash balance of $238.1M supports R&D and commercial expansion.
  • ↓Operating expenses could reach $520M in 2026, net loss $37.6M.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Ardelyx, Inc. (NASDAQ: ARDX) is a biopharmaceutical company focused on developing and commercializing innovative therapies for gastrointestinal and renal conditions. The company’s lead product is Ibsrella, which targets Irritable Bowel Syndrome with Constipation (IBSC), while also offering Exposa, designed for managing hyperphosphatemia in chronic kidney disease. Ardelyx is actively engaged in expanding its product pipeline and establishing significant market presence, reflecting a growing concern for unmet medical needs within these therapeutic areas.

Bull says

  • ↑Total revenue grew 38% YoY to $93.4M; Ibsrella sales up 58%.
  • ↑Cash balance of $238.1M supports R&D and commercial expansion.
  • ↑Phase III CIC trial and RDX10531 pipeline target $1B revenue by 2029.
  • ↑Ibsrella capture: 77% of IBS patients dissatisfied with current therapy.
  • ↑Prescription dispenses rose 32%, paid scripts up 19% vs prior year.
  • ↑High growth factor and positive analyst revisions reinforce outlook.

Bear says

  • ↓Operating expenses could reach $520M in 2026, net loss $37.6M.
  • ↓Heavy dependence on Ibsrella creates concentration risk for revenues.
  • ↓Exposa lost Part D coverage, reducing dialysis market access.
  • ↓Negative profitability and book-to-price metrics signal valuation and margin pressure.
  • ↓Rising competition from GLP-1 therapies may disrupt market share.
  • ↓High sensitivity to interest rates may amplify downside in rising-rate environment.

Investment themes with ARDX

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-02-2026bullish

Transcript signals

Bull points

  • It's great to be with all of you today.
  • 2026 is poised to be another significant year of growth for our company, and we're already off to a great start.
  • At Ardellix, we're building an innovative pipeline of medicines for patients with unmet medical needs. Our first quarter's performance reinforces our confidence in the strategy we've laid out and in our ability to capture the opportunities ahead to create long-term value.

Bear points

  • Our net loss for the first quarter of 2026 was $37.6 million, or a loss of 15 cents per share, compared to a net loss of $41.1 million, or 17 cents per share, for the same period in 2025.
Read full transcript analysis ›